pharmaceutical · input
Modified guanosine cap structures added co-transcriptionally during mRNA in vitro transcription to enable ribosome translation. TriLink BioTechnologies (Maravai LifeSciences) held near-monopoly through CleanCap technology used in virtually all approved mRNA COVID vaccines.
4
Source countries
3
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on mrna cap analogs (cleancap, co-transcriptional) somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| USUnited States | 72% |
| DEGermany | 15% |
| JPJapan | 8% |
| CNChina | 5% |
Who makes it
3 companies produce mrna cap analogs (cleancap, co-transcriptional).
San Diego-based mRNA capping reagent company (subsidiary of Maravai LifeSciences, MRVI); inventor of CleanCap co-transcriptional capping technology; near-monopoly during COVID-19 vaccine era with 350+ preclinical/clinical programs using CleanCap; revenue peaked at $883M (2022), fell to $259M (2024) after COVID demand collapse
US CDMO (owned by Danaher since 2021) based in Fargo, ND; supplies plasmid DNA, mRNA, and proteins for cell and gene therapy; in February 2025 entered non-exclusive CleanCap license with TriLink to produce M6, AG, AG 3'OMe, and AU cap analogs for clinical mRNA manufacturing
German specialty nucleotide manufacturer; supplies ARCA (Anti-Reverse Cap Analog) and other cap analogs, modified nucleotides, and IVT (in vitro transcription) reagents for research and pharmaceutical-grade mRNA synthesis
